ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
TWICE PER WEEK TESTOSTERONE INJECTIONS ARE ASSOCIATED WITH GREATER RISK OF HIGH HEMATOCRIT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="GreenMachineX" data-source="post: 154937" data-attributes="member: 15245"><p><span style="font-size: 15px"><strong>MP76-05 TWICE PER WEEK DOSING OF INTRAMUSCULAR TESTOSTERONE (T) IS ASSOCIATED WITH GREATER RISK OF ERYTHROCYTOSIS</strong></span></p><p></p><p>I wish they had tried 50 mg twice per week instead of 80-150 mg twice per week.</p><p></p><p>INTRODUCTION AND OBJECTIVES</p><p>With an increasing awareness for mens health, marketing for pharmaceutical sales of testosterone products has increased over 170% over the last 5 years as reported by Layton et. al with a 100-fold increase in the market over the last 3 decades. The most common dose-limiting adverse effect of testosterone therapy (TTh) is erythrocytosis, which may exacerbate pre-existing vascular disease and increase the risk for thromboembolic complications. The increased risk of erythrocytosis with injectable testosterone over that of topical applications has been established. We sought to determine if the incidence of erythrocytosis, as defined by a hematocrit (Hct) > 52%, in patients on injectable TTh was significantly changed by more frequent, lower dose T injections.</p><p></p><p>METHODS</p><p>A sample of 55 men using injectable T (cypionate or enanthate) for symptomatic hypogonadism at a single dose and frequency was selected for analysis from a single center mens health database. Age, T dosage, frequency of administration, duration of T therapy, and Hct were extracted through retrospective chart review. The cohorts were separated into 27 men on 200mg of T once weekly (QW) and 28 men on <strong>80-160mg</strong> of T twice weekly (BIW). Indication for BIW dosing was a return of hypogonadal symptoms prior to the administration of the next dose. The maximum Hct was identified for each individual and the cohort mean of the maxima was calculated. The difference in numerical variables was assessed via Mann-Whitney U analysis.</p><p></p><p>RESULTS</p><p>No significant difference was identified between the mean (range) age of the QW and BIW cohorts (43.2 (27-63) years vs. 40.6 (27-62) years), respectively (p=0.36). Erythrocytosis occurred in 11% of the QW cohort with a maximum Hct (Interquartile Range) of 49.2 % (43.4, 54.6). In contrast, a maximum Hct of 51.4 % (45.7, 56.9) was observed in the BIW cohort, with 29% of men developing erythrocytosis. Statistical significance was identified in comparing the percent erythrocytosis of the two cohorts (p=0.007). The rate of erythrocytosis, defined as the number of days until maximum Hct while on testosterone, was comparable in both groups (p=0.18).</p><p></p><p>CONCLUSIONS</p><p>Although the rate of erythrocytosis is comparable among BIW and QW dosing, more frequent dosing of injectable T is associated with a higher maximum Hct and a higher incidence of erythrocytosis. These data suggest that dosing frequency, rather than total T dose, is an important factor in development of erythrocytosis in men on injectable TTh.</p><p></p><p></p><p><a href="https://www.auajournals.org/doi/full/10.1016/j.juro.2016.02.1856" target="_blank">American Urological Association</a></p><p></p><p>According to this study someone on another forum posted, twice per week injections was associated with higher hematocrit than once per week injections. Anyone have any thoughts?</p></blockquote><p></p>
[QUOTE="GreenMachineX, post: 154937, member: 15245"] [SIZE=15px][B]MP76-05 TWICE PER WEEK DOSING OF INTRAMUSCULAR TESTOSTERONE (T) IS ASSOCIATED WITH GREATER RISK OF ERYTHROCYTOSIS[/B][/SIZE] I wish they had tried 50 mg twice per week instead of 80-150 mg twice per week. INTRODUCTION AND OBJECTIVES With an increasing awareness for mens health, marketing for pharmaceutical sales of testosterone products has increased over 170% over the last 5 years as reported by Layton et. al with a 100-fold increase in the market over the last 3 decades. The most common dose-limiting adverse effect of testosterone therapy (TTh) is erythrocytosis, which may exacerbate pre-existing vascular disease and increase the risk for thromboembolic complications. The increased risk of erythrocytosis with injectable testosterone over that of topical applications has been established. We sought to determine if the incidence of erythrocytosis, as defined by a hematocrit (Hct) > 52%, in patients on injectable TTh was significantly changed by more frequent, lower dose T injections. METHODS A sample of 55 men using injectable T (cypionate or enanthate) for symptomatic hypogonadism at a single dose and frequency was selected for analysis from a single center mens health database. Age, T dosage, frequency of administration, duration of T therapy, and Hct were extracted through retrospective chart review. The cohorts were separated into 27 men on 200mg of T once weekly (QW) and 28 men on [B]80-160mg[/B] of T twice weekly (BIW). Indication for BIW dosing was a return of hypogonadal symptoms prior to the administration of the next dose. The maximum Hct was identified for each individual and the cohort mean of the maxima was calculated. The difference in numerical variables was assessed via Mann-Whitney U analysis. RESULTS No significant difference was identified between the mean (range) age of the QW and BIW cohorts (43.2 (27-63) years vs. 40.6 (27-62) years), respectively (p=0.36). Erythrocytosis occurred in 11% of the QW cohort with a maximum Hct (Interquartile Range) of 49.2 % (43.4, 54.6). In contrast, a maximum Hct of 51.4 % (45.7, 56.9) was observed in the BIW cohort, with 29% of men developing erythrocytosis. Statistical significance was identified in comparing the percent erythrocytosis of the two cohorts (p=0.007). The rate of erythrocytosis, defined as the number of days until maximum Hct while on testosterone, was comparable in both groups (p=0.18). CONCLUSIONS Although the rate of erythrocytosis is comparable among BIW and QW dosing, more frequent dosing of injectable T is associated with a higher maximum Hct and a higher incidence of erythrocytosis. These data suggest that dosing frequency, rather than total T dose, is an important factor in development of erythrocytosis in men on injectable TTh. [URL='https://www.auajournals.org/doi/full/10.1016/j.juro.2016.02.1856']American Urological Association[/URL] According to this study someone on another forum posted, twice per week injections was associated with higher hematocrit than once per week injections. Anyone have any thoughts? [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
TWICE PER WEEK TESTOSTERONE INJECTIONS ARE ASSOCIATED WITH GREATER RISK OF HIGH HEMATOCRIT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top